These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 25060991

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
    Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, Roccaro AM, Ghobrial IM.
    Clin Cancer Res; 2011 Jul 01; 17(13):4389-99. PubMed ID: 21521775
    [Abstract] [Full Text] [Related]

  • 4. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK, Gan ZY, Fitter S, To LB, Zannettino AC.
    Leuk Res; 2015 Mar 01; 39(3):380-7. PubMed ID: 25624048
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL, Park A, Akiyama R, Tap WD, Denny CT, Federman N.
    PLoS One; 2015 Mar 01; 10(9):e0133610. PubMed ID: 26402468
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A.
    Oncogene; 2014 Jan 16; 33(3):316-25. PubMed ID: 23318440
    [Abstract] [Full Text] [Related]

  • 9. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
    Wang S, Niu X, Bao X, Wang Q, Zhang J, Lu S, Wang Y, Xu L, Wang M, Zhang J.
    Oncol Rep; 2019 May 16; 41(5):2636-2646. PubMed ID: 30896825
    [Abstract] [Full Text] [Related]

  • 10. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM.
    Clin Cancer Res; 2011 Apr 01; 17(7):1753-64. PubMed ID: 21355079
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
    Safaroghli-Azar A, Bashash D, Kazemi A, Pourbagheri-Sigaroodi A, Momeny M.
    Eur J Pharmacol; 2019 Jan 05; 842():89-98. PubMed ID: 30401630
    [Abstract] [Full Text] [Related]

  • 13. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
    Okabe S, Tanaka Y, Tauchi T, Ohyashiki K.
    Ann Hematol; 2019 Mar 05; 98(3):723-733. PubMed ID: 30430191
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
    Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK.
    Mol Cancer Res; 2015 Feb 05; 13(2):263-72. PubMed ID: 25232031
    [Abstract] [Full Text] [Related]

  • 15. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P, Wen X, Wang B, Hou D, Zou H, Yuan Q, Yang H, Xie J, Huang H.
    Ann Hematol; 2018 May 05; 97(5):865-875. PubMed ID: 29450644
    [Abstract] [Full Text] [Related]

  • 16. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E, Driscoll JJ.
    Oncotarget; 2016 Jun 21; 7(25):38523-38538. PubMed ID: 27229530
    [Abstract] [Full Text] [Related]

  • 17. Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
    Netland IA, Førde HE, Sleire L, Leiss L, Rahman MA, Skeie BS, Miletic H, Enger PØ, Goplen D.
    J Neurooncol; 2016 Aug 21; 129(1):57-66. PubMed ID: 27283525
    [Abstract] [Full Text] [Related]

  • 18. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
    Wu YL, Zhang LI, Trandafir L, Dong T, Duval V, Hazell K, Xu B.
    Anticancer Res; 2016 Nov 21; 36(11):6185-6194. PubMed ID: 27793950
    [Abstract] [Full Text] [Related]

  • 19. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
    Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J.
    Cancer Res; 2006 Oct 01; 66(19):9714-21. PubMed ID: 17018630
    [Abstract] [Full Text] [Related]

  • 20. Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.
    Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.
    Cancer Res; 2018 May 15; 78(10):2732-2746. PubMed ID: 29472518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.